Bemotrizinol: The First New FDA Sunscreen Ingredient in 25 Years

Bemotrizinol retains over 90% of its UV-filtering capacity after hours of direct sun exposure, making it one of the most photostable broad-spectrum filters ever evaluated by the FDA. On December 11, 2025, the agency issued a proposed administrative order to add this ingredient to the US sunscreen monograph at concentrations up to 6%, marking the first new sunscreen active considered for American consumers since 1999.

For anyone who has followed the sunscreen science gap between the US and the rest of the world, this is a significant regulatory shift. Bemotrizinol has been formulated into sunscreens across Europe, Asia, and Australia for over two decades. The US is catching up, and the chemistry behind this ingredient explains why dermatologists and photobiologists have been advocating for its inclusion.

This article explains how bemotrizinol works at the molecular level, why it outperforms the current US standard (avobenzone), what the safety data shows, and what the FDA timeline means for consumers.

How Bemotrizinol Absorbs UV Radiation

Bemotrizinol absorbs radiation across both the UVB (280-320 nm) and UVA (320-400 nm) spectra, a range that most individual UV filters cannot cover alone. Its molecular structure contains multiple chromophores that dissipate absorbed UV energy as heat through a process called internal conversion, returning the molecule to its ground state without breaking down. This is the foundation of its photostability.

The practical implication is straightforward: bemotrizinol does not need to be reapplied as frequently due to chemical degradation. Standard reapplication guidelines (every two hours, or after swimming) still apply because of physical removal from the skin, but the filter itself remains chemically intact throughout exposure. Testing data submitted to the FDA shows that formulations containing 6% bemotrizinol maintained consistent SPF and UVA-PF values across extended UV irradiation protocols.

This stability also benefits other filters in the same formulation. Bemotrizinol acts as a triplet-state quencher for avobenzone, absorbing the excited-state energy that would otherwise trigger avobenzone's photodegradation pathway. In multi-filter sunscreens, bemotrizinol functions as both an active UV absorber and a stabilizer for less robust ingredients.

Why Avobenzone Falls Short and Bemotrizinol Fills the Gap

Avobenzone has been the primary UVA filter in US sunscreens for decades, but it has a well-documented structural weakness: keto-enol tautomerism. Under UV irradiation, avobenzone shifts from its UV-absorbing enol form to a keto form that absorbs in the UVC range and is prone to photodegradation. The keto form generates a long-lived triplet state that produces singlet oxygen and free radicals, both of which further degrade the molecule and can stress the skin.

Formulators have worked around this limitation by pairing avobenzone with stabilizers like octocrylene, but these workarounds add complexity and cost without fully solving the problem. Independent testing has shown that avobenzone-based formulations can lose 30-50% of their UVA protection within 60-90 minutes of sun exposure, depending on formulation quality.

Bemotrizinol does not undergo this degradation cycle. Its molecular geometry allows it to absorb and release UV energy repeatedly without structural change. Where avobenzone is a consumable resource in a sunscreen formulation, bemotrizinol functions more like a catalyst, doing its job without being used up. This distinction matters for real-world protection, particularly during extended outdoor activity where consistent UVA coverage is critical for preventing photoaging and DNA damage.

The Safety Profile: 20 Years of Global Data

In a clinical pharmacokinetic Maximum Usage Trial (MUsT) submitted to the FDA, maximal topical applications of 6% bemotrizinol resulted in plasma concentrations that rarely exceeded the agency's 0.5 ng/mL safety threshold, with no evidence of accumulation over repeated application. This is a meaningful data point because the FDA has flagged several existing US sunscreen ingredients for exceeding this threshold in similar trials.

The low systemic absorption is consistent with bemotrizinol's molecular weight (607.8 g/mol), which is large enough to limit penetration through the stratum corneum. Smaller UV filters pass through the skin barrier more readily, which is why the FDA has required additional safety studies for ingredients like oxybenzone and homosalate. Bemotrizinol's size and lipophilicity keep it on the skin surface where it belongs.

Irritation and sensitization data are equally favorable. Clinical studies across multiple skin types show low rates of contact dermatitis and no phototoxic or photoallergic reactions at the proposed 6% concentration. The ingredient has been approved for use in over 50 countries, including for children aged 6 months and older, and post-market surveillance across two decades has not surfaced significant safety signals.

The FDA Timeline and What Consumers Should Expect

The FDA's proposed administrative order opened a public comment period that closed on January 26, 2026. Assuming no major objections or requests for additional data, a final order is expected by summer 2026. Once the order is finalized, manufacturers can begin marketing sunscreens containing bemotrizinol without needing individual product approvals, since OTC monograph ingredients are approved by category.

Product development timelines suggest that major sunscreen brands could have bemotrizinol formulations on US shelves by late 2026 or early 2027. Some brands already sell bemotrizinol-containing products internationally, so reformulating for the US market is primarily a regulatory and supply chain exercise rather than a formulation challenge.

For consumers, the arrival of bemotrizinol means access to sunscreens with more robust UVA protection, better photostability, and potentially more elegant cosmetic textures. European and Asian sunscreen formulations have long benefited from a broader palette of approved UV filters, and bemotrizinol's addition narrows that gap meaningfully. It does not eliminate it, since other filters like Tinosorb M (bisoctrizole) and Mexoryl SX (ecamsule) remain unavailable in the US monograph, but it is the most consequential single addition possible.

If you currently use a sunscreen that relies on avobenzone for UVA protection, watch for bemotrizinol-containing alternatives as they become available. The photostability advantage alone makes it worth the switch, and the 20-year global safety record provides a level of real-world confidence that newly developed ingredients cannot match.